These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 19904267

  • 1. Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
    Wagner AD, Buechner-Steudel P, Moehler M, Schmalenberg H, Behrens R, Fahlke J, Wein A, Behl S, Kuss O, Kleber G, Fleig WE.
    Br J Cancer; 2009 Dec 01; 101(11):1846-52. PubMed ID: 19904267
    [Abstract] [Full Text] [Related]

  • 2. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O, Elsayed Z, Elhalawani H.
    Cochrane Database Syst Rev; 2018 Apr 06; 4(4):CD011746. PubMed ID: 29624208
    [Abstract] [Full Text] [Related]

  • 3. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    Fiteni F, Jary M, Monnien F, Nguyen T, Beohou E, Demarchi M, Dobi E, Fein F, Cleau D, Fratté S, Nerich V, Bonnetain F, Pivot X, Borg C, Kim S.
    BMC Gastroenterol; 2014 Aug 13; 14():143. PubMed ID: 25117717
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater.
    Sohn BS, Yuh YJ, Kim KH, Jeon TJ, Kim NS, Kim SR.
    Tumori; 2013 Aug 13; 99(2):139-44. PubMed ID: 23748804
    [Abstract] [Full Text] [Related]

  • 5. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.
    Verderame F, Russo A, Di Leo R, Badalamenti G, Santangelo D, Cicero G, Valerio MR, Gulotta G, Tomasello G, Gebbia N, Fulfaro F.
    Ann Oncol; 2006 Jun 13; 17 Suppl 7():vii68-72. PubMed ID: 16760298
    [Abstract] [Full Text] [Related]

  • 6. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
    Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF, BINGO investigators.
    Lancet Oncol; 2014 Jul 13; 15(8):819-28. PubMed ID: 24852116
    [Abstract] [Full Text] [Related]

  • 7. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
    Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, Jang JS, Jeung HC, Kang JH, Lee HW, Shin DB, Kang HJ, Sun JM, Park JO, Park YS, Kang WK, Lim HY.
    Lancet Oncol; 2012 Feb 13; 13(2):181-8. PubMed ID: 22192731
    [Abstract] [Full Text] [Related]

  • 8. INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.
    Patt YZ, Murad W, Fekrazad MH, Baron AD, Bansal P, Boumber Y, Steinberg K, Lee SJ, Bedrick E, Du R, Lee FC.
    Cancer Med; 2017 Sep 13; 6(9):2042-2051. PubMed ID: 28801995
    [Abstract] [Full Text] [Related]

  • 9. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, Nasti G, Montano M, Amatu A, Aprile G, Cagnazzo C, Fasola G, Siena S, Ciuffreda L, Reni M, Aglietta M.
    Cancer; 2016 Feb 15; 122(4):574-81. PubMed ID: 26540314
    [Abstract] [Full Text] [Related]

  • 10. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Gong JF, Zhang XD, Li J, Di LJ, Jin ML, Shen L.
    Ai Zheng; 2007 Aug 15; 26(8):890-4. PubMed ID: 17697554
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
    Hezel AF, Noel MS, Allen JN, Abrams TA, Yurgelun M, Faris JE, Goyal L, Clark JW, Blaszkowsky LS, Murphy JE, Zheng H, Khorana AA, Connolly GC, Hyrien O, Baran A, Herr M, Ng K, Sheehan S, Harris DJ, Regan E, Borger DR, Iafrate AJ, Fuchs C, Ryan DP, Zhu AX.
    Br J Cancer; 2014 Jul 29; 111(3):430-6. PubMed ID: 24960403
    [Abstract] [Full Text] [Related]

  • 12. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
    Knox JJ, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ.
    Ann Oncol; 2004 May 29; 15(5):770-4. PubMed ID: 15111345
    [Abstract] [Full Text] [Related]

  • 13. Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Wagner AD, Buechner-Steudel P, Wein A, Schmalenberg H, Lindig U, Moehler M, Behrens R, Kleber G, Kuss O, Fleig WE.
    Ann Oncol; 2007 Jan 29; 18(1):82-87. PubMed ID: 17030546
    [Abstract] [Full Text] [Related]

  • 14. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
    Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E.
    Invest New Drugs; 2005 Aug 29; 23(4):369-75. PubMed ID: 16012797
    [Abstract] [Full Text] [Related]

  • 15. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.
    Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS.
    Dig Dis Sci; 2008 Feb 29; 53(2):564-70. PubMed ID: 17597402
    [Abstract] [Full Text] [Related]

  • 16. A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
    Lassen U, Jensen LH, Sorensen M, Rohrberg KS, Ujmajuridze Z, Jakobsen A.
    Acta Oncol; 2011 Apr 29; 50(3):448-54. PubMed ID: 20670085
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma.
    Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP, Pan BR.
    World J Gastroenterol; 2008 Sep 07; 14(33):5210-6. PubMed ID: 18777599
    [Abstract] [Full Text] [Related]

  • 18. Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis.
    Ramaswamy A, Ostwal V, Pinninti R, Kannan S, Bhargava P, Nashikkar C, Mirani J, Banavali S.
    J Hepatobiliary Pancreat Sci; 2017 May 07; 24(5):262-267. PubMed ID: 28196310
    [Abstract] [Full Text] [Related]

  • 19. Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma.
    Cassier PA, Thevenet C, Walter T, Baulieux J, Scoazec JY, Bancel B, Adham M, Souquet JC, Ponchon T, Lombard-Bohas C.
    Eur J Gastroenterol Hepatol; 2010 Sep 07; 22(9):1111-7. PubMed ID: 20386107
    [Abstract] [Full Text] [Related]

  • 20. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.
    Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, Koppenhöfer U, Hochhaus A, Stieler J, Trojan J, Gregor M, Klump B.
    Br J Cancer; 2008 Jan 29; 98(2):309-15. PubMed ID: 18182984
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.